Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Operating Income (2022 - 2024)

Summit Therapeutics (SMMT) has disclosed Operating Income for 3 consecutive years, with -$65.6 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Operating Income fell 81.2% year-over-year to -$65.6 million, compared with a TTM value of -$226.0 million through Dec 2024, up 62.93%, and an annual FY2024 reading of -$226.0 million, up 62.93% over the prior year.
  • Operating Income was -$65.6 million for Q4 2024 at Summit Therapeutics, down from -$58.4 million in the prior quarter.
  • Across five years, Operating Income topped out at -$15.8 million in Q2 2023 and bottomed at -$537.2 million in Q1 2023.
  • Average Operating Income over 3 years is -$94.7 million, with a median of -$42.4 million recorded in 2024.
  • Peak annual rise in Operating Income hit 92.11% in 2024, while the deepest fall reached 277.47% in 2024.
  • Year by year, Operating Income stood at -$16.9 million in 2022, then plummeted by 113.75% to -$36.2 million in 2023, then plummeted by 81.2% to -$65.6 million in 2024.
  • Business Quant data shows Operating Income for SMMT at -$65.6 million in Q4 2024, -$58.4 million in Q3 2024, and -$59.6 million in Q2 2024.